Patient, Care Partner, and Physician Voices in Treatment Decision-Making for Multiple Myeloma
Lisa Dwyer Orr,Dee Lin,Bingcao Wu,Thomas LeBlanc,Beth Faiman,Jenny Ahlstrom,Margaret Yung,Kathleen Deering,Victoria Kulbokas,Joshua Feldman,Erika Kline,Noa Biran
DOI: https://doi.org/10.2147/ppa.s474722
2024-10-20
Patient Preference and Adherence
Abstract:Lisa Dwyer Orr, 1 Dee Lin, 1 Bingcao Wu, 1 Thomas W LeBlanc, 2 Beth Faiman, 3 Jenny Ahlstrom, 4 Margaret Yung, 5 Kathleen L Deering, 5 Victoria Kulbokas, 5 Joshua L Feldman, 6 Erika Kline, 6 Noa Biran 7 1 Janssen Scientific Affairs LLC, Titusville, NJ, USA; 2 Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA; 3 Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA; 4 HealthTree Foundation, Draper, UT, USA; 5 EPI-Q Inc, Chicago, IL, USA; 6 Inspire Insights, Arlington, VA, USA; 7 Hackensack Meridian Health, John Theurer Cancer Center, Hackensack, NJ, USA Correspondence: Lisa Dwyer Orr, Janssen Scientific Affairs LLC, Titusville, NJ, USA, Tel +1 561 290-9901, Email Introduction: Treatment decision-making for multiple myeloma (MM) is complex. Individuals involved in decision-making may value treatment attributes differently based on their role as a patient, care partner, or physician. This study describes those attributes, and what is most important by role. Methods: We conducted a cross-sectional online survey with consenting adult patients with MM, MM care partners, and physicians treating MM. Respondents were recruited from US panels (Inspire and M3 Global Research) between September and December 2022. Survey items were informed by a targeted literature review, qualitative interviews, and a steering committee comprising clinical experts, a patient advocate, patient, and care partner. Descriptive statistics were generated and reported in aggregate. Results: Email invitations were sent to 8071 Inspire members interested in or posting about MM. Of these, 4427 viewed the invitation, 941 responded, and 156 patients and care partners completed the survey (17% of respondents). For physicians, 5588 were invited via Email by M3 Global Research, with 761 viewing the invitation, 214 accessing the survey link, and 137 completing the survey (64% of respondents). Duration of response, side effects, and patients' quality-of-life (QoL) were the top three treatment attributes selected across the three cohorts; alignment of these attributes was consistent among patients regardless of disease severity. Separately, patients rated QoL and the amount of caregiving needed during/after treatment as the most important factors for future treatment decisions. If more effective MM treatments were offered, care partners were more willing to assume greater family burden (77%) compared to patients (49%), and patients were more accepting of potential serious side effects (50%) than were care partners (34%). Conclusion: Patients with MM, care partners, and physicians consider and value various treatment decision-making factors. Recognizing and addressing these differences is critical to meeting patients' preferences, needs, and optimizing patient outcomes. Keywords: Decision-making, treatment choice, cross-sectional survey, multiple myeloma Multiple myeloma (MM) is a rare hematologic cancer, with an estimated incidence of 35,730 in 2023; it accounts for approximately 1.8% of all new cancer cases in 2023. 1 Despite its relatively low incidence, it ranks as the 15th leading cause of cancer-related deaths in the United States (US). 1 Treatment for MM has improved significantly over the years, leading to improved survival rates and quality of life (QoL) for patients. However, there are still several challenges due to the disease's heterogeneity and evolving treatment landscape, making it difficult to establish a definitive standard of care for all patients. 2–4 Several factors need to be considered when choosing an appropriate therapy, including age, disease severity, potential toxicities, responses to previous therapies, and number of previous therapy lines. 5 Despite high initial treatment response rates in patients with newly diagnosed MM, acquired drug resistance remains a significant challenge, resulting in shorter duration of response for subsequent lines of treatment. 5 Considering the many therapies available, varying patient characteristics, and potential side effects, choosing the most appropriate treatment plan can be challenging. In addition, involving patients and their care partners in the decision-making process is crucial to achieving and maintaining the desired QoL for the patient. Many therapies can also be burdensome to patients and care partners; patients must carefully consider their options and balance the potential benefits of therapy with the possible side effects and impact on their QoL. 6–8 Research demonstrates that patients' treatment decisions are sig -Abstract Truncated-
medicine, general & internal